CCL21 and hepatocellular carcinoma: We constructed Hepa1-6-derived subcutaneous HCC mouse models and treated them with IgG, anti-PD-1 antibody, recombinant murine CCL21, and anti-PD-1 antibody combined with CCL21, respectively (Fig. 4A).